Olmesartan/Amlodipin/Hct Ratiopharm (Olmesartan Medoxomil, Hydrochlorothiazide, Amlodipine Besilate)

Olmesartan/Amlodipin/Hct Ratiopharm is used in the management of hypertension, acting on several pathways that regulate vascular tone and fluid balance.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Resistant hypertension: provides additional blood pressure reduction when monotherapy is insufficient.
• Hypertensive patients with edema: counteracts calcium‑channel blocker‑induced peripheral edema.
• Hypertension with concomitant fluid retention: promotes natriuresis and diuresis to aid blood pressure control.

• The combination works by three complementary mechanisms: olmesartan blocks the angiotensin II type 1 receptor, preventing vasoconstriction; amlodipine besilate inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation; and hydrochlorothiazide increases urinary sodium and water excretion by inhibiting sodium‑chloride reabsorption in the distal convoluted tubule, reducing plasma volume.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Peripheral edema
• Flushing
• Fatigue
• Cough

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Electrolyte disturbances (e.g., hyponatremia, hyperkalemia)
• Angio‑edema
• Liver enzyme elevations
• Pancreatitis

When prescribing this combination, clinicians should consider several safety aspects.

• Renal function: assess baseline creatinine and monitor periodically.
• Electrolytes: check serum potassium and sodium levels, especially with diuretic component.
• Hepatic impairment: use with caution in patients with liver disease.
• Pregnancy: avoid use during pregnancy due to fetal risk.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan/Amlodipin/Hct Ratiopharm may interact with several drug classes.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): may cause excessive potassium loss and renal dysfunction.
• Potassium‑saving diuretics or supplements: increase risk of hyper‑kalemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): raise amlodipine plasma levels.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect and affect renal function.
• Lithium: can increase lithium concentrations, risking toxicity.
• Other antihypertensives: may cause additive blood pressure lowering.
• Antacids containing aluminium or magnesium: may reduce absorption of olmesartan.